Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 683 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eczema Clear all
Recruiting Phase 2 Interventional

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

NCT06524635
View directory record Official record
Conditions
Hidradenitis Suppurativa, Atopic Dermatitis
Interventions
Lutikizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Sacramento, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 23, 2026, 6:55 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07487831
View directory record Official record
Conditions
Atopic Dermatitis (Eczema), Psoriasis
Interventions
Sodium chloride tablets, Placebo Tablets
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis

NCT00690807
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PH-10
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

NCT03569293
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis

NCT01065714
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Hydrogel vehicle, Eucerin Lotion
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 1Phase 2 Interventional

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

NCT00125333
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
NF-kappaB Decoy
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Miami, Florida • Fridley, Minnesota • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
14
States / cities
Fountain Valley, California • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis

NCT03559075
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 23, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, JNJ-95475939, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Eczema

NCT04214548
View directory record Official record
Conditions
Eczema
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 23, 2026, 6:55 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating TRIV-509 in Atopic Dermatitis

NCT07167758
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TRIV-509, Placebo
Drug
Lead sponsor
Triveni Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

Combination Therapy for Atopic Dermatitis

NCT00119158
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Combination of pimecrolimus and fluticasone, pimecrolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 23, 2026, 6:55 PM EDT
Completed No phase listed Observational

Etiology of Eczema Herpeticum (EH)

NCT03038932
View directory record Official record
Conditions
Eczema Herpeticum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 64 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05724199
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

NCT05923099
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Fremont, California • Los Angeles, California • Fort Myers, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

NCT00121316
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 23, 2026, 6:55 PM EDT
Completed No phase listed Observational

Bone Health in Patients With Atopic Dermatitis

NCT03800004
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 6:55 PM EDT
Enrolling by invitation No phase listed Observational

Investigation of Filaggrin Gene Mutations Among Latinx Patients With Atopic Dermatitis

NCT06464133
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Results available

Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit

NCT00654355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tacrolimus ointment
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
2 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Treatment of Staphylococcus Aureus Colonization in Hand Eczema

NCT01591785
View directory record Official record
Conditions
Hand Eczema, Foot Eczema
Interventions
Retapamulin 1% ointment, Placebo
Drug
Lead sponsor
Gary Goldenberg
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Characterizing Skin Microbiome Change in Atopic Dermatitis

NCT04800185
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
Crisaborole 2% Top Oint, Skin Microbiome Swabs
Drug · Genetic
Lead sponsor
University of California, Irvine
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 23, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

Novel Topical Treatment of Hand Dermatitis (Eczema)

NCT00614289
View directory record Official record
Conditions
Contact Dermatitis, Eczema, Contact
Interventions
Epikeia Coatings
Device
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Oct 23, 2026, 6:55 PM EDT